Chronic Myeloid Leukemia Excellence Forum

Chronic Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Asciminib Continues to Demonstrate Efficacy and Tolerability Among Patients With CML in Chronic Phase

01/10/2024

Featuring David Andorsky, MD

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Videos

Management of CML: New Agents and Monitoring for MRD

10/19/2022

Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.

Ehab Atallah, MD, provides an...

10/19/2022

Oncology

Podcasts

Ponatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML

06/04/2021

Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.

Jorge Cortes, MD, shares...

06/04/2021

Oncology

Interview

Dr Atallah Assesses Outcomes Following the Discontinuation of TKIs in CML

02/16/2021

Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.

Ehab L. Atallah, MD, discusses...

02/16/2021

Oncology

Podcasts

Andreas Hochhaus, MD, Talks About the ASCEMBL Trial, Eliminating LSCs in CML

12/11/2020

In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.

In this podcast, Dr Hochhaus...

12/11/2020

Oncology

Podcasts

Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP

11/30/2020

Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.

Dr Hochhaus discusses the use of...

11/30/2020

Oncology

Interview

Study Findings Support Use of FISH to Identify Chromosomal Abnormalities in CML

10/16/2020

Zhenya Tang, MD, PhD, discusses the findings and clinical significance of a study he led on the use of FISH to identify chromosomal abnormalities in patients with CML.

Zhenya Tang, MD, PhD, discusses...

10/16/2020

Oncology

Commentary

Impact of Care Cost on TKI Adherence in Patients With CML

10/09/2020

Gary Lyman, MD, comments on the clinical significance and findings of a study he co-conducted on the link between generic imatinib availability and trends in TKI use among patients with CML.

Gary Lyman, MD, comments on the...

10/09/2020

Oncology

Podcasts

The Evolving Treatment Landscape for CML

09/26/2020

Matt Kalaycio, MD, discusses how treatment for CML has evolved in the past 2 decades, and touches on the IRIS trial, which greatly impacted the treatment landscape for this disease.

Matt Kalaycio, MD, discusses how...

09/26/2020

Oncology

Interview

TKI Therapy Interruption Recommended for Pregnant Patients With CML

09/20/2020

Elisabetta Abruzzese, MD, PhD, discusses the history of research pertaining to patients with CML who are pregnant or planning to start a family.

Elisabetta Abruzzese, MD, PhD,...

09/20/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology